Clinical Trial Transparency & Disclosures

Trusted support to meet the daily demands of pharmaceutical industry transparency requirements

The MMS team members were brilliant at performing redactions across our project!
Regulatory Operations Manager
Top 5 Pharmaceutical Sponsor

MMS provides end-to-end transparency services support, with our deep knowledge in transparency laws, global regulations, and pharmaceutical industry requirements. Sponsors like you trust MMS to alleviate the day-to-day activity burden of transparency by facilitating cross-functional engagement, ensuring legal and regulatory compliance, and enabling responsible data sharing.

We do all this while maintaining patient privacy and the protection of company confidential information.

View the depth of our Clinical Trial Transparency and Clinical Trial Disclosure Services, below.

Clinical Trial Registration and Result Disclosures Services

MMS helps Sponsors achieve and surpass clinical trial disclosures reporting requirements for clinicaltrials.gov, the European Union Clinical Trials Register (EU-CTR), EU Clinical Trial Information System (EU-CTIS), and other international registries.

Our robust services, processes, and tools allow MMS to be your centralized transparency department with the ability to manage all workflow and clinical data reporting obligations for an entire pipeline.

Anonymization and Redaction of Documents

MMS is an innovator of risk-based clinical trial document anonymization, with industry thought leadership and the use of advanced AI tools to achieve both efficiency and quality in every deliverable. Internal anonymization processes and tools are designed to maximize data utility and protect patient privacy.

Anonymization of Data Sets

Our risk-based dataset anonymization approach protects patient privacy and maximizes the data utility by keeping the risk below our predetermined threshold, and our process is proven to produce high-quality anonymized datasets with less manual effort. The anonymization of each variable is driven by a standard rule set that can be reused across multiple studies.

Our rule-building technology allows MMS to switch rules based on the personal information in each variable. Our tool can anonymize individual patient level data in different data sources, including SAS transport files, SAS7BDAT, Excel, and CSV.

Plain Language Summaries of Clinical Trial Results for Laypersons

As an industry leader in the creation of lay summaries, MMS develops programs for Sponsors to meet and exceed current and future regulations. With a team of dedicated plain language summary writers, graphic designers, lay reviewers, and project managers, the transparency specialists at MMS are focused on ensuring the success of every plain language summary created.

Our global team enables quick mobilization, 24-hour support, and the ability to scale our services to meet your needs.

Suggested For You

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules